David Dingman is a Principal of the Firm.
In his current role at RedBird, David is actively involved in the sourcing, due diligence and oversight of the Financial Services portfolio.
Prior to joining RedBird, David was the Managing Director of Shipston Group Limited, a private equity firm focused on both international and domestic investments across a wide range of industries, including automotive, biotech, real estate, and fintech. During his 13 years at Shipston Group Limited, David was instrumental in the transformation of several of the Company’s investments into global businesses, many of which were built as platform buy-and-builds. David also directed the reorganization and prioritization of investments with the focus on the monetization of legacy investments through both private and public market transactions. David was a member of Shipston’s Investment Committee, supervising all aspects of the corporate finance and M&A execution.
Among his many investments, David led Shipton’s roll up and integration of multiple high-precision machining companies and low-pressure aluminum casting suppliers to create Mobex Global. Mobex Global is a fully integrated globally trusted partner to the automotive, heavy-duty, construction, agriculture, and industrial markets, and is at the forefront of the evolving mobility industry. In addition, David positioned the IPOs of both China Maple Leaf Educational Systems and Genscript Biotech Corp, solving complicated jurisdictional and governance issues resulting in successful exits. Maple Leaf was the largest private boarding school system in China and Genscript Biotech Corp was a leading Hong Kong gene and cell therapy provider with a current market cap of $37 Billion HK.
Philanthropically, David is an Advisor Advocate for the OKU Foundation and serves on the Board of the Boston Winter Ball. David is also an advisor to the Michael and Elizabeth Dingman Foundation.
David received both his MBA and BA in History from Boston College.